The Effect of Topical Treatment With Combigan Compared to Timolol and Brimonidine on Pupil Diameter
Information source: Carmel Medical Center
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy
Intervention: Combigan (Combination of Brimonidine and Timolol) (Drug); Timolol (Drug)
Phase: Phase 2
Status: Not yet recruiting
Sponsored by: Carmel Medical Center Official(s) and/or principal investigator(s): Orna Geyer, MD, Principal Investigator, Affiliation: Carmel Medical Center
Overall contact: Orna Geyer, Professor, Phone: 97248250926, Email: orna_geyer@clalit.org.il
Summary
In this study we will explore the combined effect of Brimonidine and Timolol 0. 5%
(Combigan) eye drops on pupil dilation. It is a well studied phenoma that Brimonidine and
a miotic effect on the pupil, however the combined effect of alpha agonist and beta blocker
has not been studied.
Clinical Details
Official title: The Effect of Topical Treatment With Combigan Compared to Timolol and Brimonidine on Pupil Diameter
Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label
Primary outcome: Pupil diameter
Detailed description:
In this study we will explore the combined effect of Brimonidine and Timolol 0. 5%
(Combigan) eye drops on pupil dilation. It is a well studied phenoma that Brimonidine and
a miotic effect on the pupil, however the combined effect of alpha agonist and beta blocker
has not been studied.
The study subjects will be examined twice, two weeks apart. On the first exam the subject
will receive Combigan eye drop to the right eye and a Brimonidine drop to the left eye. The
effect on pupil size before and 30 minutes, 60 minutes, 240 minutes, and 300 minutes after
instillation of eyedrops. On the second exam the subject will receive Timolol (0. 5%) eye
drop to the right eye and a Brimonidine drop to the left eye. The effect on pupil size
before and 30 minutes, 60 minutes, 240 minutes, and 300 minutes after instillation of
eyedrops.
Eligibility
Minimum age: 18 Years.
Maximum age: 30 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Healthy adults subjects with no ocular pathology
- Non pregnant women
- Normal pupil response
Exclusion Criteria:
- Chronic topical treatment
- Systemic medication affecting autonomic nerve system
- History of intra-ocular surgery
- Irregular pupil
- History of ocular neurological or severe cardio-vascular disease
Locations and Contacts
Orna Geyer, Professor, Phone: 97248250926, Email: orna_geyer@clalit.org.il
Carmel Medical Center, Haifa 34362, Israel; Not yet recruiting Zina Goldbaum, Phone: 97248250441, Email: zinago@clalit.org.il
Additional Information
Starting date: August 2014
Last updated: August 28, 2014
|